Euroopa Liit - eesti - EMA (European Medicines Agency)

astellas pharma europe b.v. - gilteritinib dietüülfumaraat - leukeemia, müeloidne, äge - antineoplastilised ained - xospata on näidustatud monotherapy raviks täiskasvanud patsientidel, kes on taastekkinud või tulekindlad ägeda müeloidse leukeemia (aml), mille flt3 mutatsioon.

Eesti - eesti - Ravimiamet

viatris limited - dasatiniib - õhukese polümeerikattega tablett - 50mg 56tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi winthrop industrie - aspartinsuliin - diabeet mellitus - diabeetis kasutatavad ravimid - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - mitu müeloomit - antineoplastilised ained - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - mitu müeloomit - antineoplastilised ained - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

eurogenerics holdings b.v. - teriparatiid - osteoporoos - kaltsiumi homöostaas - qutavina is indicated in adults. osteoporoosi ravi postmenopausis naistel ja meestel, kellel on suurem luumurdude risk. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. ravi osteoporoosi seostatakse pidevat süsteemset glükokortikoidi ravi naiste ja meeste suurenenud risk luumurdude.

Euroopa Liit - eesti - EMA (European Medicines Agency)

theramex ireland limited - teriparatiid - osteoporoos - kaltsiumi homöostaas - livogiva is indicated in adults. osteoporoosi ravi postmenopausis naistel ja meestel, kellel on suurem luumurdude risk. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. ravi osteoporoosi seostatakse pidevat süsteemset glükokortikoidi ravi naiste ja meeste suurenenud risk luumurdude.

Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international nv - rilpivirine - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.

Euroopa Liit - eesti - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - mitu müeloomit - antineoplastilised ained - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - sigalaste immunoloogilised omadused - sead (nuumamiseks) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.